Atri, A., Shaughnessy, L., Locascio, J. J. and Growdon, J. H. (2008). Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Disease & Associated Disorders, 22, 209–221.
Burns, A., Gauthier, S. and Perdomo, C. (2007). Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 22, 806–812.
Courtney, C. et al. (2004). Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial [see comment]. Lancet, 363, 2105–2115.
Doody, R. S., Geldmacher, D. S., Gordon, B., Perdomo, C. A., Pratt, R. D. and Donepezil Study Group (2001). Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology, 58, 427–433.
Doody, R. S. et al. (2009). Donepezil treatment of patients with MCI. Neurology, 72, 1555–1561.
Ellis, K. A. et al. (2009). The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics, 21, 672–687.
Farlow, M. R. et al. (2010). Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clinical Therapeutics, 32, 1234–1251.
Feldman, H. H. et al. (2007). Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study [see comment]. Lancet Neurology, 6, 501–512.
Feldman, H. H. et al. (2009). Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. International Journal of Geriatric Psychiatry, 24, 479–488.
Geldmacher, D. S., Provenzano, G., McRae, T., Mastey, V. and Ieni, J. R. (2003). Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. Journal of the American Geriatrics Society, 51, 937–944.
Gill, S. S. et al. (2009). Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Archives of Internal Medicine, 169, 867–873.
Gillette-Guyonnet, S. et al. (2006). Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 61, 516–520.
Green, R. C. et al. (2009). Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease. JAMA, 302, 2557–2564.
Hernandez, R. K., Farwell, W., Cantor, M. D. and Lawler, E. V. (2009). Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs New England healthcare system. Journal of the American Geriatrics Society, 57, 1997–2003.
Kavanagh, S., Van Baelen, B. and Schäuble, B. (in press). Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. Journal of Alzheimer's Disease.
Lopez, O. L. et al. (2009). Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. Journal of Neurology, Neurosurgery & Psychiatry, 80, 600–607.
Mohs, R. C. et al. (2001). A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [erratum appears in Neurology, 2001, 57, 1942]. Neurology, 57, 481–488.
Petersen, R. C. et al. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment [see comment]. New England Journal of Medicine, 352, 2379–2388.
Pirttilä, T., Wilcock, G., Truyen, L. and Damaraju, C. V. (2004). Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. European Journal of Neurology, 11, 734–741.
Raschetti, R., Albanese, E., Vanacore, N. and Maggini, M. (2007). Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Medicine, 4, e338.
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P. and Damaraju, C. V. (2004). The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Archives of Neurologyl, 61, 252–256.
Rountree, S., Chan, W., Pavlik, V., Darby, E., Siddiqui, S. and Doody, R. (2009). Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Research & Therapy, 1, 7.
Schneider, L. S. and Qizilbash, N. (2004). Delay in nursing home placement with donepezil [see comment]. Journal of the American Geriatrics Society, 52, 1024–1026.
Schneider, L. S. and Sano, M. (2009). Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimer's and Dementia, 5, 388–397.
Schneider, L. S., Insel, P. S. and Weiner, M. W.(for the Alzheimer's Disease Neuroimaging Initiative) (2011). Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's disease neuroimaging initiative. Archives of Neurology, 68, 58–66.
Small, G. W., Kaufer, D., Mendiondo, M. S., Quarg, P. and Spiegel, R. (2005). Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. International Journal of Clinical Practice, 59, 473–477.
Sona, A. et al. (2012). Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. International Psychogeriatrics, 24, 196–203.
Winblad, B. et al. (2001). A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD [see comment]. Neurology, 57, 489–495.
Winblad, B. et al. (2008). Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology, 70, 2024–2035.